Qiuyan Luo1, Xue Peng2, Hua Zhang3. 1. Department of Respiratory Medicine, Sichuan Provincial Transportation Department Road Bureau Hospital Chengdu, Sichuan Province, China. 2. Department of Internal Medicine, Sichuan Provincial Transportation Department Road Bureau Hospital Chengdu, Sichuan Province, China. 3. Department of Geriatrics, Sichuan Provincial People's Hospital Chengdu, Sichuan Province, China.
Abstract
OBJECTIVES: This study focused on patients with chronic obstructive pulmonary disease (COPD) and aimed at investigating the effect of terbutaline plus doxofylline on their pulmonary function and quality of life. METHODS:Ninety COPD patients were divided by using a random number table into a control group (administration of doxofylline) and experimental group (administration of terbutaline combined with doxofylline), with 45 patients in each group. The therapeutic efficacy, pre- and post-treatment pulmonary function and the quality of life were compared between the control and experimental groups. RESULTS: After treatment, patients in the experimental group had lower levels of interleukin-8, tumor necrosis factor α and C-reactive protein (all P<0.001), higher forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEVl/FVC (all P<0.001), and lower total score of COPD assessment test (P<0.05) compared with the control group. CONCLUSION:Terbutaline combined with doxofylline for the treatment of COPD patients can efficiently decrease inflammatory factor levels, and bring them better pulmonary function and quality of life. AJTR
RCT Entities:
OBJECTIVES: This study focused on patients with chronic obstructive pulmonary disease (COPD) and aimed at investigating the effect of terbutaline plus doxofylline on their pulmonary function and quality of life. METHODS: Ninety COPDpatients were divided by using a random number table into a control group (administration of doxofylline) and experimental group (administration of terbutaline combined with doxofylline), with 45 patients in each group. The therapeutic efficacy, pre- and post-treatment pulmonary function and the quality of life were compared between the control and experimental groups. RESULTS: After treatment, patients in the experimental group had lower levels of interleukin-8, tumor necrosis factor α and C-reactive protein (all P<0.001), higher forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEVl/FVC (all P<0.001), and lower total score of COPD assessment test (P<0.05) compared with the control group. CONCLUSION:Terbutaline combined with doxofylline for the treatment of COPDpatients can efficiently decrease inflammatory factor levels, and bring them better pulmonary function and quality of life. AJTR
Authors: Griet Conickx; Pieter Mestdagh; Francisco Avila Cobos; Fien M Verhamme; Tania Maes; Bart M Vanaudenaerde; Leen J M Seys; Lies Lahousse; Richard Y Kim; Alan C Hsu; Peter A Wark; Philip M Hansbro; Guy F Joos; Jo Vandesompele; Ken R Bracke; Guy G Brusselle Journal: Am J Respir Crit Care Med Date: 2017-01-01 Impact factor: 21.405
Authors: Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Trigueros; Borja G Cosío; Ciro Casanova; Juan Antonio Riesco; Pere Simonet; David Rigau; Joan B Soriano; Julio Ancochea Journal: Arch Bronconeumol Date: 2017-05-03 Impact factor: 4.872
Authors: Mario Cazzola; Luigino Calzetta; Peter J Barnes; Gerard J Criner; Fernando J Martinez; Alberto Papi; Maria Gabriella Matera Journal: Eur Respir Rev Date: 2018-05-02